FDA Says 505(q) Petitions Pull Resources From Safety Activities

Drug Industry Daily
A A
Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agency’s public health efforts, the FDA said in a report to Congress.

To View This Article:

Login

Subscribe To Drug Industry Daily